Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the safety and tolerability of ZD6474 in combination withVinorelbine (Navelbine) or Gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genzyme, a Sanofi Company
• Treatments: Cisplatin; Gemcitabine; Vinblastine; Vinorelbine

Criteria

Inclusion Criteria:

• Confirmed non small cell lung cancer (stage IIIB-IV)

• Life expectancy greater than 12 weeks

• At least 1 measurable lesion greater than 10mm in smallest diameter.

Exclusion Criteria:

• Prior treatment with anticancer agent

• Brain metastases

• Major surgery within last 4 weeks